Sugi Predict

Sugi Predict / Compounds / SCHEMBL460460

SCHEMBL460460

SCHEMBL460460

OCC1CCN(c2ncccn2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.50
▸ ADRA1D P25100 3/20 0.47
▸ ADRA1A P35348 3/20 0.47
▸ ADRA1B P35368 3/20 0.47
▸ SORD Q00796 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.43
▸ PDE10A Q9Y233 1/20 0.43
▸ MAPK8 P45983 1/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28170205 0.82 KDM4E (0.50) KDM4ECYP2C19ALDH1A1ADRA1DADRA1A
SCHEMBL10243308 0.81 KDM4E (0.51) KDM4ECYP2C19ALDH1A1ADRA1DADRA1A
SCHEMBL453937 0.81 KDM4E (0.51) KDM4ECYP2C19ALDH1A1ADRA1DADRA1A
SCHEMBL6030119 0.81 KDM4E (0.51) KDM4ECYP2C19ALDH1A1ADRA1DADRA1A
SCHEMBL1146193 0.81 DKK1 (0.55) KDM4ECYP2C19ALDH1A1ADRA1DADRA1A
SCHEMBL10491580 0.81 KDM4E (0.51) KDM4ECYP2C19ALDH1A1ADRA1DADRA1A
SCHEMBL20893475 0.80 PDE10A (0.48) GPR119PDE10AMAPK8MAPK10
SCHEMBL384595 0.80 MAPK8 (0.46) KDM4EGAAPDE10AMAPK8MAPK10
SCHEMBL11360192 0.80 PDE10A (0.48) PDE10AMAPK8MAPK10
Hydrochloric Acid SCHEMBL8127062 0.79 DKK1 (0.53) KDM4ECYP2C19ALDH1A1ADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 — — US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 — — US disclosed
US-20230192677-A1 CYP11A1 INHIBITORS ORION CORPORATION (FI) 2023-06-22 — — US disclosed
WO-2021229152-A1 CYP11A1 INHIBITORS ORION CORPORATION (FI) 2021-11-18 — — WO disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 — — US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 — — US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 — — WO disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 — — WO disclosed
EP-2881384-B1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO LTD (JP) 2018-05-30 — — EP disclosed
US-9920075-B2 Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-20 — — US disclosed
WO-2012034038-A2 DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2012-03-15 — — WO disclosed
EP-2059516-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (publ) (SE) 2009-05-20 — — EP disclosed
US-7378418-B2 Azabicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 — — US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 — — US disclosed
WO-2008025798-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (PUBL) (SE) 2008-03-06 — — WO disclosed
EP-1697370-B1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-04-25 — — EP disclosed
EP-1697370-A1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS Bristol-Myers Squibb Company (US) 2006-09-06 — — EP disclosed
WO-2005063761-A1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-14 — — WO disclosed
US-20050143381-A1 Azabicyclic heterocycles as cannabinoid receptor modulators BROSTOL-MYERS SQUIBB COMPANY 2005-06-30 — — US disclosed
US-4826843-A Cerebral function enhancing diazinylpiperidine derivatives BRISTOL-MYERS (US) 1989-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192677-A1 CYP11A1 INHIBITORS CYP11B1, CYP11B2, CYP17A1 KDM4E 2869/4885CYP2C19 78/4885ALDH1A1 176/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP KDM4E 2209/4885CYP2C19 2452/4885ALDH1A1 1182/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP KDM4E 1934/4885CYP2C19 2437/4885ALDH1A1 1170/4885
US-20050143381-A1 Azabicyclic heterocycles as cannabinoid receptor modulators CNR1, CNR2, CCKBR KDM4E 1199/4885CYP2C19 226/4885ALDH1A1 1758/4885
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 KDM4E 4829/4885CYP2C19 376/4885ALDH1A1 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.